Sanofi has launched two Phase II/III trials, THESEUS and PERSEPHONE, evaluating TSLP/IL-13 bispecific antibody (BsAb) lunsekimig in 1,884 poorly controlled eosinophilic phenotype chronic obstructive pulmonary disease (COPD) patients. The studies will compare subcutaneous dosing against placebo with primary endpoint measuring annualised rate of moderate-to-severe exacerbations at 48 weeks.

Lunsekimig previously demonstrated 40.9 parts per billion reduction in fractional exhaled nitric oxide versus placebo in a Phase Ib asthma proof-of-concept study, indicating potent type 2 inflammation suppression.

The dual mechanism targeting TSLP and IL-13 represents a novel approach for COPD patients with type 2 inflammation drivers.

PharmCube's NextBiopharm® database identifies 22 TSLP-targeting BsAbs in development of which 7 are in the clinical stage, including two TSLP/IL-13 BsAbs (lunsekimig included), one targeting TSLP and IL-4Rα, one TSLP BsAb, and one each targeting IL-11, IL-4Rα and SCF. Click here to request a free trial for NextBiopharm®.